STSantiago David Silva Tobar

Santiago David Silva Tobar

*This is an algorithmically generated author record based on publicly available information.

Santiago David Silva Tobar has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autodeterminación en salud, como factor psicológico que influye en la supervivencia observacional y en la percepción de síntomas en pacientes en programas de hemodiálisis

    by Franklin Mora Bravo, Paulina Cruz Idrovo, Marcia Verónica Pozo Calderon, Diego Adolfo Vimos, Alfonso Silva Contreras, Marisol Pérez Herrera, Washington Osorio, Rafael Becerra Guerra, Nelson Rojas, Guillermina Blum, et al.

    Introduction: Self-determination in Health (SDH), defined as a patient's inherent ability to make informed and active decisions about their health care, is a modifiable psychological factor that correlates with motivation, proactive behavior, and improved physical health outcomes. In the context of hemodialysis (HD) therapy, SDH promotes functional autonomy and active patient engagement, even in the face of vulnerability; by contrast, its absence is associated with decision delegation and deterioration in health. The study hypothesizes that patients in hemodialysis programs with higher SDH will have a lower perception of symptoms and a longer survival. Methods: This observational, case-control study was carried out in 14 hemodialysis units in Ecuador from May to June 2025. Patients aged 18 years or older who were enrolled in hemodialysis programs were included. Two groups were formed: one with patients without SDH and the other with patients with SDH. The variables studied included age, duration of hemodialysis treatment, self-determination in health, adherence to treatment, labor integration, physical dependence, acceptance of kidney disease, and scores on "The Dialysis Symptom Index." A 1:1 propensity score matching (PSM) was performed between the groups based on age, sex, and presence of type 2 diabetes mellitus. The means were compared using Student's t-test, while proportions were compared using Chi-squared tests. An observational survival analysis was also conducted, examining the length of stay in the hemodialysis unit up to the date of the survey. Results: 180 patients without SDH and 184 with SDH were analyzed. Age was similar in both groups (57.9 ± 13.7 years vs. 58.0 ± 11.8 years, P = 0.938). The proportion of men was similar in both groups (51.1% vs. 51.6%; P=0.921). The prevalence of type 2 diabetes mellitus was comparable between the groups (48.3% vs. 47.3%; P=0.841). The group without SDH had a higher rate of physical dependence (53.3%) compared to the group with SDH (25.5%) (P < 0.001). Adherence was greater in the group with SDH (51.6%) than in the group without SDH (36.7%; P < 0.001). Work activity was more common among the group with SDH (38.0%) compared to 12.2% among the group without SDH (12.2%; P < 0.001). The group with SDH showed lower symptom intensity (–25.82%) than the group without SDH (P<0.001). Increased survival was observed in the SDH group, with 29.5 months versus 36.08 months in the non-SDH group (χ2, Log-Rank 7.71, P<0.005). Conclusions: Patients with SDH exhibited longer survival, significantly higher treatment adherence, and less physical dependence. Additionally, self-determination was associated with a reduction in the severity of perceived symptoms, including pain and psychological symptoms such as worry and sadness, across 18 of the 34 assessed. These findings demonstrate that SDH is not just a psychological concept but also a therapeutic goal that impacts survival. Randomized intervention studies in SDH are necessary.

  • Open Access

    Prevalence of multiple myeloma in patients on hemodialysis programs

    by David Garrido, Omar Seminario, Juan Santacruz, Evelyn Moreira, Rosalina Lituma, Jorge Moscoso, Ubelis Rosales, Alfonso Silva Contreras, Victor Hugo Ortega, Angel Quevedo, et al.

    Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.


  • Open Access

    Nefropatía inducida por Ácido Aristolóquico.

    by Wilmer Stalin Sanango Reinoso, Washington Xavier Osorio Chuquitarco, Santiago David Silva Tobar, Octavio José Salgado Ordoñez

    Introduction: Aristolochic acids contain a carboxylic nitro phenanthrene group and can be found in medicinal herbs of the genus Aristolochia. Their nephrotoxicity has been confirmed in endemic geographic areas such as the Balkans of Europe and the Central American region. The clinical findings consist of tubulointerstitial nephropathy and generally go unnoticed until the advanced stages of chronic kidney disease. Objective of the review: The aim is to describe the main pathophysiological aspects and establish diagnostic and treatment criteria in patients with Aristolochic Acid Nephropathy. Essential points of the review: About 180 types of aristolochic acids (AAs) have been discovered, the most critical types AAΙ, AAΙΙ, AAΙΙΙa (AA C) and AAΙVa (AA D), which are differentiated according to the position of their hydroxyl radical (OH), hydrogen (H) and methoxyl (OCH3). AA-induced nephropathy occurs through at least five pathways that associate the depletion of intracellular glutathione, cellular damage due to induction of cell apoptosis, direct damage to the endoplasmic reticulum, and mitochondrial damage. This produces atrophic tubular injury and interstitial fibrosis; the metabolite has a bladder neoplastic effect. Conclusion: The incidence of aristolochic acid nephropathy is probably much higher than initially thought, and its existence should be considered in patients who present with chronic kidney disease with a tubulo-interstitial clinical pattern.


  • Open Access

    Hemoperfusión en intoxicación por fósforo blanco

    by María José Pinos Cedeño, Juan Sebastian Guacho Guacho, Anthony Rosero Portilla, Santiago David Silva Tobar

    Introducción: El fósforo blanco es comúnmente utilizado en productos de pirotecnia. Cuando es ingerido puede producir alteraciones gastrointestinales, hepáticas, renales, colapso circulatorio y neurotoxicidad. No existe un antídoto y una opción de tratamiento puede ser el uso de hemoperfusión, por lo que se presenta el manejo del presente caso. Caso clínico: Hombre de 26 años, que acude con ingesta de 100 mg fósforo blanco en forma de 5 pastillas pirotécnicas (1.41 mg/kg) 5 horas previas. El examen físico con hiperetensión arterial 158/92 mm Hg, el resto del examen normal. Hemoglobina 17.8 g/dl, Colinesterasa 13216 U/L, cetonuria 150 mg/dl, toxicológico negativo para anfetaminas, barbitúricos, benzodiacepinas, cocaína, marihuana, metadona, metanfetaminas, opiáceos y antidepresivos. Manejo: Se realizó un lavado gástrico con bicarbonato de sodio al 10% (20 ampollas) más 1000 ml de Cloruro de Sodio al 0.9%. Se hidrató con Solución Salina 0.9% 100 ml/hora, Omeprazol 40 mg intravenoso y Acetilcisteína en infusión continua. Se colocó acceso vascular y fue sometido a 4 sesiones de Hemoperfusión (Jafron HA230 de carbón artivado), cada 12 horas con duración de 3 horas. Evolución: Al tercer hubo un incremento de TGP de 1002 U/l , el INR fue de 4.56. Se diagnosticó hepatitis aguda grave, sin encefalopatía, sin insuficiencia hepática aguda. Se realizó 4 sesiones adicionales de Hemoperfusión, simultáneamente recibe Vitamina K y Acetilcisteína. En el 6to día disminuyó el valor de TGP 128 U/L, y se normalizo el INR. Se dio el alta en buenas condiciones. Conclusión: La hemoperfusion en 8 sesiones en este caso de intoxicación grave por fósforo blanco, evitó la insuficiencia hepática y la mortalidad.

  • Open Access

    Prurito asociado a enfermedad renal crónica con y sin terapia de reemplazo renal.

    by Santiago David Silva Tobar, Santiago Martín Camacho Pedroza

    Introducción: El prurito asociado a enfermedad renal crónica (PA-ERC) afecta la calidad de vida, adherencia al tratamiento y aumenta la mortalidad de los pacientes con enfermedad renal crónica con y sin terapia de reemplazo renal extracorpórea (hemodiálisis o diálisis peritoneal). Su prevalencia y la intensidad de los síntomas son mayores en diálisis peritoneal (DP) comparada con hemodiálisis (HD). El diagnóstico se realiza mediante scores que evitan el sub diagnóstico. Su tratamiento se relaciona con la intensidad de los síntomas, de leves a moderados, tratamiento tópico y en los síntomas severos, sistémico. Por lo general se presenta como grandes áreas simétricas enrojecidas de la piel, a menudo por la noche. Objetivo de la revisión: El objetivo de la revisión es repasar los principales aspectos fisiopatológicos y establecer un algoritmo de diagnóstico y tratamiento del prurito en pacientes con enfermedad renal crónica con y sin requerimiento de terapia de reemplazo renal (hemodiálisis y diálisis peritoneal). Puntos importantes de la revisión: Existen varios scores diagnósticos como la escala visual analógica que mide la intensidad del prurito, la escala de Pauli-Magnus que relaciona la calidad del sueño y la 5-D itching scale que evalúa la calidad de vida, sin embargo, el KDQoL-36, WINRS y SADS resultan más prácticos al momento de la valoración. El tratamiento más reciente es la Nalfurafina, un agonista del receptor opioide k, que ha reducido la gravedad de los síntomas en un 95 %. Conclusión: No existe un algoritmo de manejo del prurito asociado a ERC en pacientes con ERC que requieren o no de HD y DP en nuestro país, conocer la fisiopatología y establecer un algoritmo permitirá disminuir el sub diagnóstico y la mortalidad en estos pacientes a través de un tratamiento adecuado.

  • Open Access

    Revisión narrativa: mortalidad en pacientes con enfermedad renal crónica 5D asociada a la obesidad.

    by Santiago David Silva Tobar, Franklin Geovany Mora Bravo, Jorge Oswaldo Quinchuela Hidalgo

    Introduction: The Rico-Fontalvo classification of chronic kidney disease associated with obesity (CKD-AO) proposes four main pathophysiological mechanisms of renal function impairment with obesity. Type 4 CKD-OA addresses the issue of obesity in patients undergoing dialysis programs. An increase in body mass index > of 30 kg/m2 in the general population is associated with a higher risk of developing cardiovascular and metabolic diseases and higher mortality. In the group of patients undergoing hemodialysis therapies, the opposite occurs. The objective of the review: The objective is to provide the reader with an update on the effect of weight, body composition, and body mass index in patients undergoing hemodialysis therapy in the short, medium, and long term. Methods: A systematic search was performed in PubMed (Medline, United States Library of Congress); the search was restricted to references with no publication date limit. Keywords in English were used. Conclusion: The increase in body mass index >25 Kg/m2 in the population group of patients undergoing hemodialysis treatments has a protective effect, decreasing mortality in studies carried out with 3 to 5 years of follow-up; At a longer follow-up time (12 years), according to observational studies, an increase in body mass index >30 kg/m2 seems to have a harmful effect equal to that of the general population. The benefit of an increase in BMI >25 kg/m2 and a decrease in mortality is more significant in men, African Americans, Hispanics, and those over 65.


  • Open Access

    Litiasis renal en un paciente con hipotiroidismo primario, reporte de caso

    by Santiago David Silva Tobar

    Introducción: La hipercalciuria idiopática 35%, la orina persistentemente ácida 13.3%, la hiperuricosuria 9.3%, la hipocitraturia 5%, hipomagnesuria 4%, hiperparatiroidismo primario 2%, hiperoxaluria 1.4% y cistinuria 1% son causas de la mayoría de re-incidencias de litiasis renal. Se presenta un caso esporádico de asociación entre litiasis renal e hipotiroidismo primario no reportada previamente. Caso clínico: Se trata de un joven de 16 años que debutó con litiasis renal (2 litos) con episodios recurrentes al sexto mes (1 calculo único en pelvis renal) que requirió litotripsia, y nuevos episodios de microlitiasis posterior. Adicionalmente el paciente presentó hematuria aislada persistente de tipo no glomerular, alopecia e intolerancia al frío. Alteraciones dietéticas con baja ingesta de agua, alta ingesta de sodio y proteínas. Taller diagnóstico: Se clasificó al paciente como portador de litiasis metabólicamente activa. El estudio metabólico estableció la presencia de hipercalciuria (calciuria> 140 y < 300 mg/día en hombres) dependiente de la dieta (absortiva tipo II), con un índice calciuria/creatinuria < 0.11mg/mg. También se diagnosticó de hipotiroidismo primario. Evolución: Con hidratación y tratamiento dietético vegano, hidroclorotiazida, reposición de citrato y levotiroxina se ha logrado disminuir la calciuria y eliminar los episodios de litiasis renal hasta el momento. Conclusión: Se debería considerar al hipotiroidismo primario como otra causa de hipercalciuria absortiva tipo II. El hipotiroidismo puede ser causa de hematuria aislada.


  • Open Access

    Frailty at the beginning of dialysis; is it a prognostic factor?

    by Santiago Silva, Cristina Milano, Gonzalo García, Anabel Abib, Carlos Díaz, Gustavo Laham

    Introduction: Frailty (F) refers to the cumulative organic damage caused by aging, as a consequence of a diminished physiological reserve. Frailty’s prevalence is 73% in dialysis. Objectives: Our aim was to identify the prevalence of F in patients starting hemodialysis (HD) or hemodiafiltration online (HDF) treatment. To asses change in frailty during a six-month period of dialysis. Patients and Methods: This prospective cohort study evaluated 67 incident patient starting-HD or HDF at one year, with a follow-up period of at least six months. The frailty was assessed by the Fried frailty method. According to this test, we divided the population in two groups: Pre-frail (0-2) and frail (3-5). Results: Mean age was 64 years, 64% were male and 92% were treated with HD. A total of 35.8% of the patients were admitted to dialysis with a prosthetic or native fistula. The prevalence of F at the beginning of dialysis was 65.7%. The mean value of Charlson index (CHI) was 5.2 ± 2. There was a significant correlation between CHI and frailty test (P<0.0001). Basal F score (n=67) improved after 6 month (n=52): 3 (2-4) versus1 (1-2) (P<0.0001). Hematocrit (28 versus 32% P=0.05) and calcium levels (8.6 and 8.9 mg/dL, P<0.002) also increased after sixth-month. Global mortality was 7.5%. In the multivariate analysis CHI (P<0.001) and albumin (P=0.003) were frailty predictors. Conclusion: The prevalence of F in patients who start dialysis therapy is high. There was an improvement in F score after six-month of dialysis treatment. Patients with higher F score had higher mortality with higher CHI.